Clinical Trials
19 trialsNCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05169684 2025-06-10
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT03562507 2024-05-20
ERICA
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04892043 2024-02-23
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1 Terminated
NCT02831933 2023-09-21
ENSIGN
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT03791398 2023-02-17
379
Brown University
Phase 1/2 Terminated
NCT04069936 2022-08-02
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILsâ„¢ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
WindMIL Therapeutics
Phase 2 Terminated
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT03952325 2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT03597009 2021-04-20
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03119428 2020-08-11
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mereo BioPharma
Phase 1 Terminated
NCT02842125 2020-06-02
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
MultiVir, Inc.
Phase 1/2 Terminated